CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 15 enrolled
Drug / intervention
LY3009104drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01398475
NCT01398475Phase 1Completed
CompareCT.gov

Relative Bioavailability of the LY3009104 Free Base Test Formulation Compared to the Reference Phosphate Salt Formulation and the Effect of Food on the Bioavailability of the Test Formulation in Healthy Subjects

Eli Lilly and Company·interventional·Posted Jul 20, 2011·Updated Apr 21, 2017

In Brief

A Phase 1 clinical trial evaluating LY3009104 for Chronic Inflammatory Disorder and Arthritis, Rheumatoid. Completed, enrolled 15 participants across 1 site.

Detailed Summary

The purpose of this trial is to assess the effect of 3 formulations on the relative bioavailability of LY3009104. Participants will receive single dose of LY3009104 on 4 separate occasions with and without food. Safety evaluation and serial pharmacokinetic (PK) samples will be collected during each treatment period. Approximately 5 to 7 days of washout period between each treatment and a follow-up visit will occur approximately 5 to 7 days after the last dose of study drug.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Inflammatory Disorder, Arthritis, Rheumatoid
CountriesSingapore
CollaboratorsIncyte Corporation

Timeline

Phase 1CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJul 20, 2011
Enrollment StartJul 1, 2011
Primary CompletionSep 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 15.0 years ago

Interventions

LY3009104drug

Administered orally